Literature DB >> 12028623

Percutaneous nephrostomy versus indwelling ureteral stents in patients with bilateral nongenitourinary malignant extrinsic obstruction.

Dong Soo Park1, Jong Ho Park, Young Tae Lee.   

Abstract

We present five cases of bilateral extrinsic ureteral obstruction in advanced nongenitourinary abdominal malignancy. They show the superiority of percutaneous nephrostomy to indwelling ureteral stents in providing diversion. We suggest that percutaneous nephrostomy drainage should be the management of choice in extrinsic obstruction by advanced abdominal malignancies.

Entities:  

Mesh：

Year:  2002        PMID： 12028623     DOI： 10.1089/089277902753716106

Source DB:  PubMed          Journal:  J Endourol        ISSN： 0892-7790            Impact factor:   2.942


  5 in total

1.  Single session removal of forgotten encrusted ureteral stents: combined endourological approach.

Authors:  Yakup Bostanci; Ender Ozden; Fatih Atac; Yarkin Kamil Yakupoglu; Ali Faik Yilmaz; Saban Sarikaya
Journal:  Urol Res       Date:  2011-12-11

2.  Prone split-leg position to manage encrusted ureteral stents in a single-stage procedure in women: Step-by-step surgical technique.

Authors:  Giovanni Scala Marchini; Fábio César Miranda Torricelli; Eduardo Mazzucchi; Miguel Srougi; Manoj Monga
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

Review 3.  Palliative management of malignant upper urinary tract obstruction.

Authors:  P Sountoulides; I Mykoniatis; N Dimasis
Journal:  Hippokratia       Date:  2014 Oct-Dec       Impact factor: 0.471

4.  Which is better in patients with hydronephrosis before radical cystectomy-percutaneous nephrostomy versus internal ureteral stents.

Authors:  Bum Sik Tae; Ja Hyeon Ku
Journal:  Transl Androl Urol       Date:  2017-12

5.  Treatment outcomes of ureteral stenting for malignant extrinsic ureteral obstruction: a comparison between polymeric and metallic stents.

Authors:  Jumpei Asakawa; Taro Iguchi; Satoshi Tamada; Noriko Ninomiya; Minoru Kato; Takeshi Yamasaki; Tatsuya Nakatani
Journal:  Cancer Manag Res       Date:  2018-08-28       Impact factor: 3.989
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.